Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.91 [0.75, 1.11] | | < 1 | | 0% | 1 study (1/-) | 82.4 % | NA | not evaluable | | crucial | - |
progression or deaths (PFS) | 1.66 [1.37, 2.01] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | important | - |
objective responses (ORR) | 0.29 [0.19, 0.45] | | > 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 0.34 [0.11, 1.06] | | < 1 | | 0% | 1 study (1/-) | 96.9 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 0.09 [0.06, 0.14] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 0.96 [0.19, 4.80] | | < 1 | | 0% | 1 study (1/-) | 52.0 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 0.19 [0.09, 0.38] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.11 [0.06, 0.18] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Alopecia TRAE (grade 3-4) | 0.96 [0.02, 48.60] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.10 [0.03, 0.27] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.09 [0.01, 0.73] | | < 1 | | 0% | 1 study (1/-) | 98.8 % | NA | not evaluable | | non important | - |
Blood creatinine increased TRAE (grade 3-4) | 0.96 [0.06, 15.44] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 0.96 [0.02, 48.60] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.16 [0.05, 0.55] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.20 [0.06, 0.69] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
Dizziness TRAE (grade 3-4) | 0.48 [0.02, 14.35] | | < 1 | | 0% | 1 study (1/-) | 66.2 % | NA | not evaluable | | non important | - |
Dry skin TRAE (grade 3-4) | 0.96 [0.02, 48.60] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
Dysgeusia TRAE (grade 3-4) | 0.96 [0.02, 48.60] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.06 [0.01, 0.50] | | < 1 | | 0% | 1 study (1/-) | 99.6 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 1.92 [0.06, 57.64] | | < 1 | | 0% | 1 study (1/-) | 35.5 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.48 [0.02, 14.35] | | < 1 | | 0% | 1 study (1/-) | 66.2 % | NA | not evaluable | | non important | - |
Mucosal inflammation TRAE (grade 3-4) | 0.03 [0.00, 0.51] | | < 1 | | 0% | 1 study (1/-) | 99.2 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.05 [0.01, 0.37] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.01 [0.00, 0.08] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.06 [0.00, 1.02] | | < 1 | | 0% | 1 study (1/-) | 97.3 % | NA | not evaluable | | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 0.24 [0.01, 5.32] | | < 1 | | 0% | 1 study (1/-) | 81.4 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.96 [0.02, 48.60] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.96 [0.02, 48.60] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 0.05 [0.00, 0.89] | | < 1 | | 0% | 1 study (1/-) | 97.8 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.08 [0.00, 1.41] | | < 1 | | 0% | 1 study (1/-) | 95.6 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.03 [0.00, 0.55] | | < 1 | | 0% | 1 study (1/-) | 99.1 % | NA | not evaluable | | non important | - |
Weight decreased TRAE (grade 3-4) | 0.48 [0.02, 14.35] | | < 1 | | 0% | 1 study (1/-) | 66.2 % | NA | not evaluable | | non important | - |